Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Luis de la Cruz"'
Autor:
Dirk Schadendorf, Caroline Robert, Reinhard Dummer, Luis de la Cruz-Merino, Paolo A Ascierto, John M Kirkwood, Georgina V Long, Jacek Mackiewicz, Richard A Scolyer, Piotr Rutkowski, Jean-Jacques Grob, Jason John Luke, Michele Del Vecchio, Mizuho Kalabis, Adnan Khattak, Matteo S Carlino, Yujie Zhao, Alexander Eggermont, Vanna Chiarion Sileni, Clemens Krepler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma. At the prespecified third inter
Externí odkaz:
https://doaj.org/article/3a3ddc48ec6449b2b77882fcccc4b11b
Autor:
Caroline Robert, Helena Escuin-Ordinas, Juan Martin-Liberal, Miguel Sanmamed, Stephane Dalle, Ana Arance, Marya Chaney, Sorilla Prey, Alfonso Berrocal, Caroline Dutriaux, Iván Márquez Rodas, Philippe Saiag, Luis de la Cruz Merino, Juan Rodríguez-Moreno, Eduardo Castañón Álvarez, Pablo Cerezuela-Fuentes, Henry Montaudie, María González Cao, Julie Charles, María Pilar López Criado, Enrique de Miguel, Elisa Funk-Brentano, Roberto Huertas, Delvys Rodríguez Abreu, Eva Muñoz Couselo, Javier Sánchez López, Sonia Maciá
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/cfa232992c194eb9b490f0ff34e0deec
Autor:
James Larkin, Jeffrey Weber, Victoria Atkinson, Michael Millward, Ivan Marquez-Rodas, Luis de la Cruz-Merino, Helen Gogas, Paolo A Ascierto, Anna Maria Di Giacomo, Veerle de Pril, Vanna Chiarion-Sileni, Stephane Dalle, Leslie Fecher, Ana Arance, Jean-Jacques Grob, Nikhil I Khushalani, Michele Del Vecchio, Mario Mandala, C Lance Cowey, Michael Schenker, Petr Arenberger, Maurice Lobo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/c281f8a682984c818531f79c5352985a
Autor:
Mariano Provencio, Luis de la Cruz-Merino, Delvys Rodriguez-Abreu, Tomás Álvaro, Marylène Lejeune, Carlos Jiménez-Cortegana, Natalia Palazón-Carrión, Alejandro Martin Garcia-Sancho, Esteban Nogales-Fernandez, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fatima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Antonio Rueda Dominguez, Maria Casanova-Espinosa, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Jorge Labrador, Antonio Salar-Silvestre, Laura Galvez-Carvajal, Margarita Sánchez-Beato, María Guirado-Risueño, Pablo Espejo-García, Victor Sánchez-Margalet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, and in cancer in general. It is well known that some immunomodulatory cells, such as myeloid derived suppressor cells (MDSCs) or r
Externí odkaz:
https://doaj.org/article/b89f60e62bf043c59fe379aa70ec66e3
Autor:
Jeffrey M. Conroy, Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Jason Zhu, Matthew Labriola, Daniele Marin, Shannon J. McCall, Jeffrey Clarke, Daniel J. George, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Luis de la Cruz-Merino, Arun Singavi, Ben George, Alexander C. MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Deepa Kasuganti, Neel Shah, Roger Day, Lorenzo Galluzzi, Mark Gardner, Carl Morrison
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each develope
Externí odkaz:
https://doaj.org/article/ba0a2468e04d487e8d2b8fe0e2e078e6
Autor:
Ralf Gutzmer, Caroline Robert, Gabriella Liszkay, Grant McArthur, Jacek Mackiewicz, Rodrigo Munhoz, Paolo Ascierto, Judit Olah, Paola Queirolo, Luis De La Cruz Marino, Kalpit Shah, Harper Forbes, Christian Hertig, Yibing Yan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/f0de46026009415e8098531206f1d714
Autor:
Carl Morrison, Sarabjot Pabla, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Devin Dressman, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Moachun Qin, Yirong Wang, Felicia L. Lenzo, Angela Omilian, Wiam Bshara, Matthew Zibelman, Pooja Ghatalia, Konstantin Dragnev, Keisuke Shirai, Katherine G. Madden, Laura J. Tafe, Neel Shah, Deepa Kasuganti, Luis de la Cruz-Merino, Isabel Araujo, Yvonne Saenger, Margaret Bogardus, Miguel Villalona-Calero, Zuanel Diaz, Roger Day, Marcia Eisenberg, Steven M. Anderson, Igor Puzanov, Lorenzo Galluzzi, Mark Gardner, Marc S. Ernstoff
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Abstract Background Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive performance. The clin
Externí odkaz:
https://doaj.org/article/956c5246c411433fb1a686b13fb6565c
Autor:
Andrew F. Hill, Victoria Atkinson, Vanna Chiarion-Sileni, Jeffrey S. Weber, Nikhil I. Khushalani, Leslie A. Fecher, Anna Maria Di Giacomo, Michael Schenker, James E. Larkin, Marcus O. Butler, Petr Arenberger, Helen Gogas, Ana Arance, Maurice Lobo, Luis de la Cruz-Merino, Jose Lutzky, C. Lance Cowey, Stéphane Dalle, Veerle de Pril, Jean-Jacques Grob, Ivan Marquez-Rodas, Mario Mandalà, Paolo A. Ascierto, Michele Del Vecchio, Michael Millward
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundSeveral therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding of their benefit‒risk profiles in order to make informed treatment decisions. Herein we characterize adjuvant nivolumab select (imm
Autor:
Lorenzo Galluzzi, Sean T. Glenn, Vincent Giamo, Alexander C. Mackinnon, Jeffrey M. Conroy, Sarabjot Pabla, Jeffrey M. Clarke, Matthew Labriola, Maya Khalil, Isabel Araujo-Fernandez, Carl Morrison, Jonathan Andreas, Rajbir Singh, Blake Burgher, Roger Day, Daniel J. George, Yirong Wang, Laura J. Tafe, Katherine G. Madden, Jason Zhu, Keisuke Shirai, Konstantin H. Dragnev, Mary Nesline, Neel Shah, Robin Jacob, Matthew Zibelman, Felicia L. Lenzo, Shannon J. McCall, Luis de la Cruz-Merino, Arun K Singavi, Antonios Papanicolau-Sengos, Daniele Marin, Pooja Ghatalia, Grace K. Dy, Ben George, Deepa Kasuganti, Wiam Bshara, Tian Zhang, Mark Gardner, Jonathan Thompson
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Digital.CSIC. Repositorio Institucional del CSIC
instname
[Background] PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04f5bdce7b6bf0c408faca117a7db272
http://hdl.handle.net/10261/213880
http://hdl.handle.net/10261/213880
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.